Europe’s “Divisional Patent Trap”: How Big Pharma Can Delay Generics Without Losing in Court
If you’ve ever wondered how a company can keep generics off the shelf for years—despite losing key legal battles—this is the mechanism.
Europe’s patent system …

Biopharma is in a talent crunch—and it’s showing up in the most unglamorous place: hiring timelines.
In the patent-to-pipeline race, speed isn’t just a competitive advantage. It’s a survival mechanism. The companies that consistently win aren’t only th…

Russia’s biosimilar story is no longer a footnote—it’s a blueprint. And if you’re only watching Western launches and Western pipelines, you’re missing the quiet buildout that could reshape oncology access, pricing dynamics, and competitive strategy acr…

Pharma has a supply-chain problem—and patents may be the missing map.
Drug shortages don’t usually start with a headline. They start with a quiet mismatch: a manufacturing line that can’t scale, a raw material that becomes constrained, a regulatory bot…

The drug patent clock is ticking—here’s how IP teams can forecast expiry before the market prices it in.
Most IP teams don’t lose because they miss the existence of a patent. They lose because they miss the timing.
In pharma, timing is everything: laun…

Pharma strategy is entering a new era—one where “knowing the market” is no longer enough.
In the past, drug market entry planning often meant stitching together fragmented signals: trial timelines, label expansions, competitor pipeline chatter, and a h…